VIKING GLOBAL INVESTORS LP's Net Worth
Estimate Recalculated Jul 31, 2025 12:11AM EST
Who is VIKING GLOBAL INVESTORS LP
VIKING GLOBAL INVESTORS LP has an estimated net worth of $23.3 Million. This is based on reported shares across multiple companies, which include FIRST DATA CORP, Wayfair Inc., Amylyx Pharmaceuticals, Inc., Adaptive Biotechnologies Corp, Zentalis Pharmaceuticals, LLC, RayzeBio, Inc., Editas Medicine, Inc., Inhibrx, Inc., Arbutus Biopharma Corp, Myovant Sciences Ltd., Roivant Sciences Ltd., PROCEPT BioRobotics Corp, BridgeBio Pharma, Inc., 4D Molecular Therapeutics, Inc., Rallybio Corp, Ginkgo Bioworks Holdings, Inc., APi Group Corp, FIGS, Inc., Urovant Sciences Ltd., Axovant Sciences Ltd., Frazier Lifesciences Acquisition Corp, STANDARD BIOTOOLS INC., and Inhibrx Biosciences, Inc..
SEC CIK
VIKING GLOBAL INVESTORS LP's CIK is 0001103804
Past Insider Trading and Trends
2015 was VIKING GLOBAL INVESTORS LP's most active year for acquiring shares with 12 total transactions. VIKING GLOBAL INVESTORS LP's most active month to acquire stocks was the month of January. 2016 was VIKING GLOBAL INVESTORS LP's most active year for disposing of shares, totalling 6 transactions. VIKING GLOBAL INVESTORS LP's most active month to dispose stocks was the month of March. 2014 saw VIKING GLOBAL INVESTORS LP paying a total of $430,238.88 for 146,761 shares, this is the most they've acquired in one year. In 2016 VIKING GLOBAL INVESTORS LP cashed out on 30,638,952 shares for a total of $0.00, their largest year based on trade value.
Attention insiders:Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
